- Home
- XAIR vs NCNA Comparison
XAIR vs NCNA Comparison
Compare XAIR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | NCNA |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.8M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XAIR | NCNA |
|---|---|---|
| Price | $0.81 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 138.6K | 44.3K |
| Earning Date | 02-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.03 |
| 52 Week High | $3.78 | $10.00 |
Technical Indicators
Market Signals| Indicator | XAIR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 61.30 |
| Support Level | $0.76 | $2.07 |
| Resistance Level | $0.80 | $2.27 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 76.35 | 88.06 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.